<?xml version="1.0" encoding="UTF-8"?>
<p id="Par15">Jinhua Qinggan have been used as adjuvant therapy for COVID-19 in clinical practice. In this study, 123 COVID-19 outpatients were randomly divided into a treatment group (Jinhua Qinggan combined with routine treatment for 5 days, n = 82) and a control group (routine treatment only, n = 41). The addition of Jinhua Qinggan significantly alleviated fever, cough, fatigue, sputum, anxiety, and the hospitalization rate tended to be lower than in the control group [
 <xref ref-type="bibr" rid="CR13">13</xref>]. Although a randomized controlled study, the sample size was small. Jinhua Qinggan is recommended for treating patients during the medical observation period in the NHC guidelines [
 <xref ref-type="bibr" rid="CR6">6</xref>].
</p>
